Pursuant to Regulation 30 of the SEBI (Listng Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith Investor Presentation for the quarter and half year ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories, a pharmaceutical company focused on Paediatrics, Gynaecology, Orthopaedics, and General Medicine, shared its Q2 FY26 investor presentation. Revenue declined 2.82% YoY to ₹1,292.63 lacs, while EBITDA rose 11.62% to ₹194.46 lacs, pushing EBITDA margin to 15.04% (up from 13.10%). Net profit fell 5.30% to ₹140.36 lacs, but EPS improved to ₹2.85 from ₹2.00. For H1 FY26, revenue dipped 5.60% to ₹2,377.99 lacs, though EBITDA grew 6.63% to ₹201.90 lacs. Management attributed the revenue decline to a planned scale-down of low-margin factory B2B sales and rationalization of unprofitable headcount, and highlighted that the company has gone three consecutive quarters without any external funding.
Margin expansion and the highest-ever EBITDA signal improving operational quality, even as top-line shrinks by design. The self-funded, debt-free stance and focus on profitable growth may support valuation, though the continued revenue contraction warrants close tracking of whether H2 FY26 delivers the guided efficiency improvements.